News | August 30, 2021
Granules India receives approval from Health Canada for arthritis drug
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
ranules now has a total of 38 ANDA approvals from US FDA.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The inspection is now closed, and no regulatory action has been recommended
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Subscribe To Our Newsletter & Stay Updated
